

1.6.3 Patient Information leaflet (PIL)

PREGNANCY & LACTATION USE PRECAUTIONS :

No reports of its use in pregnancy and lactation have been located. This drug is risk category C.

ADVERSE REACTIONS :

Transient symptoms of stinging and burning may occur. Conjunctival vascular congestion and true allergy may occur but are unusual. Ciliary spasm, temporal or supraorbital headache, and induced myopia may occur, all consequent to drug-induced contraction of the ciliary muscle. Systemic toxicity following appropriate topical ocular administration is extremely rare.

DOSAGE AND ADMINISTRATION :

For single-dose intraocular use only. Discard unused portion. Open under aseptic conditions only. Gently instill no more than 0.5 ml into the anterior chamber. Miosis is usually maximal 2 to 5 minutes after application.

SUPPLY :

Aurocarpine 0.5%w/v is supplied in amber vial and 5 vials in one box.

STORAGE CONDITION :

Store below 30°C



Manufactured by:

AUROLAB,

No.1, Sivagangai Main Road,

Veerapanjan,

Madurai - 625 020, (INDIA).

Phone : +91-94892 12354 / +91-73395 71000

Email: info@aurolab.com

Web : www.aurolab.com

Issue : 05

TSPMED : 08

Date : 24.12.2020

Instructions for use leaflet

AUROCARPINE

(Pilocarpine Nitrate Ophthalmic Solution 0.5% w/v)

DESCRIPTION :

Aurocarpine is clear, colorless solution. Each ml contains 5 mg of Pilocarpine Nitrate. It is used as direct acting miotic.

CLINICAL PHARMACOLOGY :

Aurocarpine produces miosis through contraction of the iris sphincter muscle, which pulls the iris root away from the trabecular meshwork in angle-closure glaucoma and allows aqueous humor to exit the eye, thereby lowering the IOP. It also causes ciliary muscle contraction, resulting in accommodation and increased tension on and opening of the trabecular meshwork spaces, facilitating aqueous humor outflow and lowering IOP in open-angle glaucoma.

Aurocarpine penetrates the cornea well and produces a low incidence of allergic reactions. It is inactivated by tissues of the anterior segment of the eye, partly by reversible binding of the drug to tissues but also by appreciable enzymatic hydrolysis to the primary metabolite, pilocarpic acid. The mean elimination half-life is 0.76 hours following 5 mg 3 times per day for 2 days.

INDICATIONS :

To induce miosis during surgery

CONTRAINDICATIONS :

Hypersensitivity to any component of the formulation; where constriction is undesirable.

PRECAUTIONS :

Caution is advised in patients with acute cardiac failure, bronchial asthma, peptic ulcer, hyperthyroidism, Glspasm, urinary tract obstruction, Parkinson's disease, recent MI, hypertension or hypotension.